中国民康医学
中國民康醫學
중국민강의학
MEDICAL JOURNAL OF CHINSEE PEOPLE HEALTH
2015年
2期
41-42,78
,共3页
奥氮平%奋乃静%老年痴呆
奧氮平%奮迺靜%老年癡呆
오담평%강내정%노년치태
Olanzapine%Perphenazine%Senile dementia
目的：：比较奥氮平与奋乃静治疗老年痴呆患者精神症状的疗效及安全性。方法：将60例老年痴呆患者随机分为奥氮平组30例及奋乃静组30例，治疗8周，以BEHAVE-AD量表评估治疗效果，以TESS量表评估患者不良反应。结果：治疗后，两组患者BEHAVE-AD评分均较治疗前减分明显(P<0.01)，但两组患者间治疗前后BEHAVE-AD减分值差异无统计学意义(P>0.05)。不良反应奥氮平组患者多见嗜睡，食欲增加，体重增加；奋乃静组多见椎体外系反应。结论：奥氮平与奋乃静治疗老年痴呆精神症状疗效相当，且不良反应均较少。
目的：：比較奧氮平與奮迺靜治療老年癡呆患者精神癥狀的療效及安全性。方法：將60例老年癡呆患者隨機分為奧氮平組30例及奮迺靜組30例，治療8週，以BEHAVE-AD量錶評估治療效果，以TESS量錶評估患者不良反應。結果：治療後，兩組患者BEHAVE-AD評分均較治療前減分明顯(P<0.01)，但兩組患者間治療前後BEHAVE-AD減分值差異無統計學意義(P>0.05)。不良反應奧氮平組患者多見嗜睡，食欲增加，體重增加；奮迺靜組多見椎體外繫反應。結論：奧氮平與奮迺靜治療老年癡呆精神癥狀療效相噹，且不良反應均較少。
목적：：비교오담평여강내정치료노년치태환자정신증상적료효급안전성。방법：장60례노년치태환자수궤분위오담평조30례급강내정조30례，치료8주，이BEHAVE-AD량표평고치료효과，이TESS량표평고환자불량반응。결과：치료후，량조환자BEHAVE-AD평분균교치료전감분명현(P<0.01)，단량조환자간치료전후BEHAVE-AD감분치차이무통계학의의(P>0.05)。불량반응오담평조환자다견기수，식욕증가，체중증가；강내정조다견추체외계반응。결론：오담평여강내정치료노년치태정신증상료효상당，차불량반응균교소。
Objective:To compare efficacy and safety of Olanzapine with Perphenazine in treatment of senile dementia. Meth-ods:60 cases of senile dementia were randomly divided into Olanzapine group of 30 cases and Perphenazine group of 30 cases, 8 weeks of treatment. The efficacy and adverse reactions were evaluated with BEHAVE-AD scale and TESS scale, respectively. Re-sults:After the treatment, BEHAVE-AD scale score decreased significantly (P<0. 01) and there was no difference in the reducing score of BEHAVE-AD between the two groups (P>0. 05). The adverse reactions of Olanzapine group were mainly lethargy, increased appetite, weight gain and those of Perphenazine group were mainly extrapyramidal symptoms. Conclusions:Olanzapine and Perphena-zine are both effective drugs for senile dementia, but Olanzapine has less adverse reactions.
